InvestorsHub Logo
Followers 26
Posts 2330
Boards Moderated 0
Alias Born 03/02/2017

Re: None

Wednesday, 04/05/2017 10:03:31 AM

Wednesday, April 05, 2017 10:03:31 AM

Post# of 37328
Before ...."Beyond the sequential improvements in gross margins and reduced operating expenses, 2016, overall, was a year of noteworthy progress for the Company. For the first time, we launched two new products and successfully completed two clinical trials in a single year. The doubling of our menu to four assays will promote our objective of continually expanding our customer footprint and increasing our revenue per customer."

And then there were 5 FDA approvals for diagnostic tests. Going to be a good year.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.